Table 3. Risks of Adenoma and Advanced Adenoma Occurrence by Quartiles of Parameters of Lipid Metabolism.
| Markers of lipid metabolism (mg/dL) | Advanced adenoma occurrence | Advanced adenoma occurrence | ||
|---|---|---|---|---|
| Crude HR (95% CI) | Adjusted HR (95% CI)* | Crude HR (95% CI) | Adjusted HR (95% CI)* | |
| Triglycerides | ||||
| Q1 (28–78) | 1 | 1 | 1 | 1 |
| Q2 (79–111) | 1.17 (0.98–1.40) | 1.02 (0.88–1.26) | 1.62 (0.83–3.18) | 1.35 (0.68–2.66) |
| Q3 (112–160) | 1.31 (1.10–1.57) | 1.13 (0.94–1.35) | 1.30 (0.64–2.64) | 1.01 (0.49–2.06) |
| Q4 (161–1967) | 1.48 (1.25–1.76) | 1.19 (0.99–1.42) | 1.52 (0.76–3.03) | 1.01 (0.50–2.07) |
| p for trend | <0.001 | 0.041 | 0.382 | 0.758 |
| Total cholesterol | ||||
| Q1 (98–180) | 1 | 1 | 1 | 1 |
| Q2 (181–201) | 0.99 (0.83–1.18) | 0.96 (0.81–0.15) | 2.15 (1.08–4.29) | 2.11 (1.06–4.21) |
| Q3 (202–226) | 1.04 (0.88–1.24) | 0.95 (0.80–1.12) | 1.39 (0.67–2.90) | 1.16 (0.55–2.43) |
| Q4 (227–433) | 1.18 (0.99–1.40) | 1.11 (0.93–1.31) | 1.48 (0.71–3.11) | 1.44 (0.69–3.02) |
| p for trend | 0.053 | 0.307 | 0.651 | 0.842 |
| LDL cholesterol | ||||
| Q1 (27–106) | 1 | 1 | 1 | 1 |
| Q2 (107–127) | 1.06 (0.89–1.26) | 1.00 (0.84–1.20) | 1.20 (0.59–2.44) | 1.12 (0.55–2.28) |
| Q3 (128–149) | 1.06 (0.89–1.27) | 0.97 (0.81–1.16) | 1.66 (0.86–3.22) | 1.52 (0.78–2.95) |
| Q4 (150–277) | 1.26 (1.06–1.50) | 1.17 (0.98–1.39) | 1.26 (0.62–2.59) | 1.23 (0.60–2.53) |
| p for trend | 0.013 | 0.123 | 0.338 | 0.389 |
| HDL cholesterol | ||||
| Q1 (20–44) | 1 | 1 | 1 | 1 |
| Q2 (45–51) | 0.98 (0.83–1.16) | 1.02 (0.86–1.20) | 0.83 (0.44–1.58) | 0.90 (0.47–1.70) |
| Q3 (52–60) | 0.90 (0.76–1.07) | 0.93 (0.78–1.10) | 0.82 (0.43–1.53) | 0.83 (0.43–1.57) |
| Q4 (61–136) | 0.91 (0.76–1.07) | 1.04 (0.88–1.24) | 0.81 (0.43–1.53) | 1.03 (0.54–1.96) |
| p for trend | 0.160 | 0.964 | 0.498 | 0.930 |
| Apolipoprotein B | ||||
| Q1 (23–79) | 1 | 1 | 1 | 1 |
| Q2 (80–94) | 1.18 (0.98–1.43) | 1.10 (0.90–1.33) | 1.37 (0.63–2.99) | 1.25 (0.57–2.73) |
| Q3 (95–109) | 1.10 (0.91–1.34) | 0.97 (0.80–1.18) | 1.41 (0.65–3.04) | 1.16 (0.54–2.51) |
| Q4 (110–215) | 1.35 (1.12–1.63) | 1.18 (0.97–1.42) | 1.60 (0.76–3.37) | 1.26 (0.59–2.69) |
| p for trend | 0.004 | 0.199 | 0.240 | 0.622 |
| Apolipoprotein A1 | ||||
| Q1 (62–120) | 1 | 1 | 1 | 1 |
| Q2 (121–133) | 0.89 (0.74–1.07) | 0.91 (0.76–1.09) | 1.41 (0.71–2.80) | 1.42 (0.71–2.83) |
| Q3 (134–148) | 0.85 (0.71–1.02) | 0.89 (0.74–1.07) | 0.81 (0.38–1.76) | 0.86 (0.40–1.88) |
| Q4 (149–285) | 0.84 (0.70–1.01) | 0.89 (0.74–1.07) | 0.90 (0.43–1.89) | 0.97 (0.46–2.06) |
| p for trend | 0.055 | 0.198 | 0.445 | 0.610 |
CI, confidence interval; HR, hazard ratio; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
*Estimated from Cox proportional hazards model adjusted for age, sex, smoking status, family history of colorectal cancer, use of nonsteroidal anti-inflammatory drugs, obesity, and initial colonoscopy finding (normal, low-risk, and high-risk groups).